Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial

Today there is plausible evidence both on experimental and epidemiological basis,that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (ckd). nevertheless,the role of serum uric acid lowering treatment in ckd is still a matter of serious controversy. review of randomised controlled trials,suggests that there may be an improvement of renal function with allopurinol treatment in ckd stage 3–5. however,these studies have included a relatively limited number of participants and provide insufficient information on adverse events and on the incidence of the end stage renal disease. therefore,before adequately powered randomised,placebo-controlled trials are completed we cannot recommend treating asymptomatic hyperuricemia in patients with ckd. © 2017